Skip to content
DraconiticResearch
Search Sources API
194,216 studies31 sourcesUpdated 25 min ago
Peer-reviewedCC BYJournal of clinical medicine

Systemic Immune–Inflammation Index Predicting Acute Cardiovascular Outcomes

  • Yasmee Khan1
  • Sudesh Prajapathi2
  • Mahadev Meena1
  • M Sukumar1
  • Shaurya Tewari1
  • Akshara Ashok1
  • Ananthakrishnan M3
  • Bhushan Shah2
  1. 1Department of General Medicine, All India Institute of Medical Sciences (AIIMS) Bhopal, Saket Nagar, Bhopal 462020, Madhya Pradesh, India
  2. 2Department of Cardiology, All India Institute of Medical Sciences (AIIMS) Bhopal, Saket Nagar, Bhopal 462020, Madhya Pradesh, India
  3. 3Department of Community & Family Medicine, All India Institute of Medical Sciences (AIIMS) Bhopal, Saket Nagar, Bhopal 462020, Madhya Pradesh, India
Read full textPDFDOICite

Abstract

Background/Objectives: Acute coronary syndrome (ACS) and acute decompensated heart failure (ADHF) are associated with substantial short-term morbidity and mortality. The systemic immune–inflammation index (SII) reflects inflammatory and thrombotic activity, but its prognostic value beyond conventional biomarkers and clinical risk scores remains uncertain. This study aimed to evaluate the prognostic value of SII for short-term major adverse cardiovascular events (MACEs) and assess its incremental value beyond established biomarkers and clinical risk scores. Methods: In this prospective observational study, 555 adults with ACS or ADHF were enrolled. Admission SII was calculated from the complete blood count. The primary outcome was 30-day MACE. Multivariable logistic regression evaluated the independent association between log-transformed SII (lnSII) and outcomes. Receiver operating characteristic analyses compared SII with cardiac troponin, BNP, and CRP in the overall cohort. GRACE and TIMI risk scores, and their incremental performance after the addition of SII, were evaluated specifically in the ACS subgroup. Results: Among the 555 patients (mean age 55.9 ± 9.8 years; 54.6% women), 59.5% experienced the primary outcome of 30-day MACE. Elevated lnSII independently predicted 30-day MACE (adjusted OR 2.31, 95% CI 1.61–3.32; p < 0.001). Lower LVEF, lower eGFR, and higher ln-troponin I and ln-BNP levels were also independent predictors of 30-day MACE. SII showed moderate discrimination (AUC 0.72), comparable to BNP and superior to CRP. Among patients with ACS, incorporation of SII significantly improved discrimination of the GRACE score (AUC 0.82 to 0.86) and TIMI score (AUC 0.76 to 0.81). Conclusions: SII independently predicts short-term adverse cardiovascular outcomes in patients with ACS and ADHF. In the ACS subgroup, SII provided incremental prognostic information beyond established GRACE and TIMI risk scores, supporting its potential role as a complementary biomarker for early risk stratification.

Related

  1. Predictive Value of the Systemic Immune-Inflammation Index for Cardiovascular Events in Patients With Chronic Total Coronary Occlusion
    Yuhao Zhao, Ping Wang, Shun Zhao +4
    Reviews in cardiovascular medicinePeer-reviewedCC BYFull textCardiovascular medicineEurope PMC
  2. Association of systemic immune-inflammation index with all-cause, cardiovascular and cancer-related mortality in cancer survivors : A population-based cohort study
    Lian Song, Haitao Zhu, Xiongfeng Cao +2
    MedicinePeer-reviewedCC BY-NCFull textGeneral medicineEurope PMCPMC
  3. Preoperative Systemic Immune-Inflammation Index and Clinical Outcomes After Coronary Artery Bypass Grafting: A Systematic Review and Meta-analysis
    S. Nourian, K. Jalalian Rad, M. Ghasemi +5
    medRxivPreprintCC BY-NC-NDFull textCardiovascular medicinemedRxiv
  4. The Aldosterone–Immune Axis in Primary Aldosteronism: Linking Adrenal Pathogenesis to Systemic Inflammation and Target-Organ Damage
    Noorzaileen Eileena Zaidi, Elena Aisha Azizan, Adli Ali
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Association of the Systemic Immune-Inflammation Index with Ascending Aortic Diameter and Dilatation: A Retrospective Cross-Sectional Study
    Selin Yılmaz, Mert Nahir, Ataç Çelik
    Medicina (Kaunas, Lithuania)Peer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{khan2026systemic,
  title = {{Systemic Immune–Inflammation Index Predicting Acute Cardiovascular Outcomes}},
  author = {Yasmee Khan and Sudesh Prajapathi and Mahadev Meena and M Sukumar and Shaurya Tewari and Akshara Ashok and Ananthakrishnan M and Bhushan Shah},
  journal = {Journal of clinical medicine},
  year = {2026},
  month = sep,
  doi = {10.3390/jcm15197605},
  url = {https://europepmc.org/article/PMC/PMC13666506},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Systemic Immune–Inflammation Index Predicting Acute Cardiovascular Outcomes
AU  - Yasmee Khan
AU  - Sudesh Prajapathi
AU  - Mahadev Meena
AU  - M Sukumar
AU  - Shaurya Tewari
AU  - Akshara Ashok
AU  - Ananthakrishnan M
AU  - Bhushan Shah
PY  - 2026
DA  - 2026/09/30
JO  - Journal of clinical medicine
DO  - 10.3390/jcm15197605
UR  - https://europepmc.org/article/PMC/PMC13666506
AB  - Background/Objectives: Acute coronary syndrome (ACS) and acute decompensated heart failure (ADHF) are associated with substantial short-term morbidity and mortality. The systemic immune–inflammation index (SII) reflects inflammatory and thrombotic activity, but its prognostic value beyond conventional biomarkers and clinical risk scores remains uncertain. This study aimed to evaluate the prognostic value of SII for short-term major adverse cardiovascular events (MACEs) and assess its incremental value beyond established biomarkers and clinical risk scores. Methods: In this prospective observational study, 555 adults with ACS or ADHF were enrolled. Admission SII was calculated from the complete blood count. The primary outcome was 30-day MACE. Multivariable logistic regression evaluated the independent association between log-transformed SII (lnSII) and outcomes. Receiver operating characteristic analyses compared SII with cardiac troponin, BNP, and CRP in the overall cohort. GRACE and TIMI risk scores, and their incremental performance after the addition of SII, were evaluated specifically in the ACS subgroup. Results: Among the 555 patients (mean age 55.9 ± 9.8 years; 54.6% women), 59.5% experienced the primary outcome of 30-day MACE. Elevated lnSII independently predicted 30-day MACE (adjusted OR 2.31, 95% CI 1.61–3.32; p < 0.001). Lower LVEF, lower eGFR, and higher ln-troponin I and ln-BNP levels were also independent predictors of 30-day MACE. SII showed moderate discrimination (AUC 0.72), comparable to BNP and superior to CRP. Among patients with ACS, incorporation of SII significantly improved discrimination of the GRACE score (AUC 0.82 to 0.86) and TIMI score (AUC 0.76 to 0.81). Conclusions: SII independently predicts short-term adverse cardiovascular outcomes in patients with ACS and ADHF. In the ACS subgroup, SII provided incremental prognostic information beyond established GRACE and TIMI risk scores, supporting its potential role as a complementary biomarker for early risk stratification.
SN  - 2077-0383
ER  -